• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy
ConclusionsThe combined effects of ARBs on ESRD and CVD and mortality in patients with diabetic nephropathy vary considerably between patients. A substantial proportion of patients remain at high risk for both outcomes despite ARB treatment.
Source: Diabetes, Obesity and Metabolism - August 11, 2016 Category: Endocrinology Authors: N. G. C. Sande, J. A. N. Dorresteijn, F. L. J. Visseren, J. P. Dwyer, P. J. Blankestijn, Y. Graaf, H. L. J. Heerspink Tags: ORIGINAL ARTICLE Source Type: research

Individualized prediction of the effect of angiotensin receptor inhibition on renal and cardiovascular outcomes in patients with diabetic nephropathy
Conclusions The combined effects of ARBs on ESRD and CVD and mortality in patients with diabetic nephropathy varies considerably between patients. A substantial proportion of patients remain at high risk for both outcomes despite ARB treatment.
Source: Diabetes, Obesity and Metabolism - June 23, 2016 Category: Endocrinology Authors: Nicolette G.C. van der Sande, Jannick A.N. Dorresteijn, Frank. L.J. Visseren, Jamie P. Dwyer, Peter J. Blankestijn, Yolanda van der Graaf, Hiddo L. Heerspink Tags: ORIGINAL ARTICLE Source Type: research

Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non–Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial)
Conclusions In this cohort of patients with type 2 diabetes with nephropathy, serum bicarbonate level associations with kidney disease end points were not retained after adjustment for estimated glomerular filtration rate, which is in contrast to results of earlier studies in nondiabetic populations.
Source: American Journal of Kidney Diseases - August 21, 2015 Category: Urology & Nephrology Source Type: research

Visit-to-Visit Variability in Blood Pressure and Kidney and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Nephropathy: A Post Hoc Analysis From the RENAAL Study and the Irbesartan Diabetic Nephropathy Trial
Conclusions In diabetic individuals with nephropathy, systolic blood pressure visit-to-visit variability is associated independently with hard kidney disease outcomes.
Source: American Journal of Kidney Diseases - October 29, 2014 Category: Urology & Nephrology Source Type: research

Diabetics Taking Certain Blood Pressure Drugs At Lower Risk Of Heart Disease
Two drugs, telmisartan and valsartan, which are used to reduce blood pressure in people with diabetes, are associated with a lower risk of hospitalization for heart attack, stroke or heart failure, according to a study published in CMAJ (Canadian Medical Association Journal). For people with type 2 diabetes, disease-related vascular illnesses are the main causes of death. Angiotensin-receptor blockers including telmisartan, valsartan, candesartan, irbesartan and losartan, are generally used interchangeably to control blood pressure...
Source: Health News from Medical News Today - July 10, 2013 Category: Consumer Health News Tags: Hypertension Source Type: news

Two ARBs Lower Risk of CVD Complications in DiabeticsTwo ARBs Lower Risk of CVD Complications in Diabetics
Compared with irbesartan, the use of telmisartan and valsartan lowered the risk of hospital admission for MI, stroke, or heart failure by 15% and 14%, respectively. The reduction was driven primarily by a reduction in the risk of heart-failure hospitalizations. Heartwire
Source: Medscape Today Headlines - July 8, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Telmisartan, valsartan lower risk of CVD complications in diabetics
Compared with irbesartan, the use of telmisartan and valsartan lowered the risk of hospital admission for MI, stroke, or heart failure by 15% and 14%, respectively. The reduction was driven primarily by a reduction in the risk of heart-failure hospitalizations.
Source: theHeart.org - July 8, 2013 Category: Cardiology Source Type: news

Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
We examined each outcome individually in secondary analyses, in addition to all-cause mortality. RESULTS:We identified 54 186 patients with diabetes who started taking an angiotensinreceptor blocker during the study period. After multivariable adjustment, patients who took either telmisartan (adjusted hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.74-0.97) or valsartan (adjusted HR 0.86, 95% CI 0.77-0.95) had a lower risk of the composite outcome compared with patients who took irbesartan. In contrast, no significant difference in risk was seen between other angiotensin-receptor blockers and irbesartan. In secondar...
Source: cmaj - July 8, 2013 Category: Journals (General) Authors: Antoniou T, Camacho X, Yao Z, Gomes T, Juurlink DN, Mamdani MM Tags: CMAJ Source Type: research